Navigation Links
Pharma, Biotech Clinical Trial Leaders to Convene for 3rd Annual DrugDev Summit to Promote Collaboration, Technology Innovation, Engaged Sites, and More Informed Patients
Date:9/14/2017

DrugDev, a QuintilesIMS company, will gather the most innovative minds in pharma and biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. The DrugDev Summit is a two-day collaborative conference that brings together the world’s most progressive clinical research leaders for best practice case studies, keynote presentations, lively breakout sessions, hands-on training, and previews of new DrugDev technology-based solutions.

Featuring a client-driven agenda and highlighted by inspiring industry keynotes (announcements to come soon), last year’s Summit welcomed expert speakers from host company Merck, Janssen, Pfizer, Novartis, Eli Lilly, ICON, Boehringer-Ingelheim, Incyte, Alkermes, BioMarin, Chesapeake IRB, Radiant Research, and Emerson Clinical Research Institute. Register for the 2017 DrugDev Summit here.

“The 2016 DrugDev Summit was a very engaging event,” said Dawn Furey, Executive Director/Head, Global Operations, at Merck. “I didn’t think I would stay for the entire two days given my competing priorities, but I couldn’t step away. It was great.”

DrugDev expects more than 125 clinical leaders to attend this year’s Summit, which promotes three pillars of clinical research optimization – collaboration, standardization, and a beautiful technology experience – to transform the quality, transparency and efficiency of clinical trials. Summit participants gain actionable advice and inspiration from sponsors, sites and patients as they network in an organized yet congenial setting. The invitation-only event is complimentary for all sponsors, CROs and sites using DrugDev technology on nearly 2,000 clinical programs.

DrugDev President and CEO Ibs Mahmood said, “Imagine the best minds in pharma and biotech gathering together, all fearless in their dedication to changing everything to speed the delivery of many more new treatments to millions of patients, and there you have the DrugDev Summit. I’m always awed by the brilliant insights and the interactions among professionals who just want to get it done for patients. I expect this year to be especially exciting as customers share their experiences standardizing on the DrugDev Spark™ unified suite across entire, massive clinical programs, and I’m very much looking forward to seeing what they can accomplish next.”

summit(at)drugdev.com with questions or for more information.

About DrugDev

DrugDev, a QuintilesIMS company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on nearly 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14687535.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
2. Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
3. Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia
4. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
5. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
6. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
7. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, will present a clinical abstract on Allogeneic Adipose Stem Cell Bio-Distribution at the Veterinary Orthopedic
8. Global Licensing Partnering Report: Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016 - Research and Markets
9. Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma
10. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
11. VetStem Biopharma, Inc., Announces the Opening of its GMP Cell Therapy Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... BARBARA, Calif. (PRWEB) , ... December 18, 2018 ... ... innovation and business process optimization firm for the life sciences industry, unveiled a ... educational content while creating a more user-friendly browsing experience for their valued clients ...
(Date:12/13/2018)... ... 11, 2018 , ... Researchers at Worcester Polytechnic Institute (WPI) ... Clostridium difficile (C. diff), a dangerous and sometimes fatal gastrointestinal infection. The sensor ... used onsite in doctor’s offices and nursing homes, providing results in minutes instead ...
(Date:12/13/2018)... FRANKLIN, Wis. (PRWEB) , ... December 13, 2018 ... ... HACCP scope which now includes food (human) ingredient. This has been part of ... Having a Food Safety Plan and certification creates custom fermentation opportunities for MDG ...
(Date:12/5/2018)... ... 2018 , ... The incredible life story of former refugee and LG Sonic ... Carlos Moedas, the European Commissioner for Research and Innovation. , In his November ... Commissioner Moedas spoke at length of Yousef’s life and journey, citing the man who ...
Breaking Biology Technology:
(Date:12/19/2018)... ROCHELLE, Va. (PRWEB) , ... December 19, 2018 , ... ... former Scientific Reviewer and Compliance Officer at the FDA Center for Devices and Radiological ... with NDA Partners as an Expert Consultant since 2015, and she has more than ...
(Date:12/18/2018)... ... December 18, 2018 , ... The nation’s leader in ... marketing. The technology has been effective at reducing patient acquisition costs by over ... with clients nationwide on patient acquisition marketing programs. Traditional marketing for stem cell ...
(Date:12/14/2018)... (PRWEB) , ... December 14, 2018 , ... ... patent number 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by ... date of October 21, 2014. The patent is an invention by uBiome collaborators ...
Breaking Biology News(10 mins):